Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen

Journal of Clinical Oncology

Volumn 28, Issue 29, 2010, Pages

  Ferraldeschi, Roberta ^a,b   Howell, Sacha J ^a   Thompson, Alastair M ^c,d   Newman, William G ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYTOCHROME P450 2D6 INHIBITOR; ESTROGEN RECEPTOR; OXIDOREDUCTASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER RECURRENCE; CLINICAL PRACTICE; DEPRESSION; DRUG EFFICACY; GENETIC VARIABILITY; GENOTYPE; HOT FLUSH; HUMAN; LETTER; PHARMACOGENETICS; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT DISEASE; SAMPLE SIZE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CYTOCHROME P-450 CYP2D6; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; NEOPLASM RECURRENCE, LOCAL; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79951901358     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.1887     Document Type: Letter

References (13)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Johnson MD, Zuo H, Lee KH, et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159, 2004 (Pubitemid 38987269)
3. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003 (Pubitemid 38008898)
4. Jin Y, Desta Z, Stearns V, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005
5. Borges S, Desta Z, Li L, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006 (Pubitemid 43946844)
6. Chubak J, Buist DS, Boudreau DM, et al: Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112:123-132, 2008
7. Lash TL, Cronin-Fenton D, Ahern TP, et al: Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 49:305-312, 2010
8. Dezentjé VO, van Blijderveen NJ, Gelderblom H, et al: Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423-2429, 2010
9. Aubert RE, Stanek EJ, Yao J, et al: Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 27:9s, 2009 (suppl; abstr CRA508)
10. Kelly CM, Juurlink DN, Gomes T, et al: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. BMJ 340:c693, 2010
11. Thompson A, Quinlan P, Bray S, et al: CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy. In Proc Am Soc Clin Oncol Breast Cancer Symposium, San Francisco, CA, October 8-10, 2009 (abstr 35)
12. Schroth W, Goetz MP, Hamann U, et al: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436, 2009
13. Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9:576-586, 2009